Joseph P Uberti
Overview
Explore the profile of Joseph P Uberti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
631
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Modi D, Kim S, Shatta M, Deol A, Kin A, Ayash L, et al.
Bone Marrow Transplant
. 2024 May;
59(8):1196-1198.
PMID: 38778149
No abstract available.
2.
Modi D, Alkassis S, Kim S, Kin A, Deol A, Ayash L, et al.
Leuk Lymphoma
. 2023 May;
64(7):1285-1294.
PMID: 37154379
Total-body irradiation (TBI)-based conditioning regimen is preferred in acute lymphoblastic leukemia (ALL). We retrospectively evaluated allogeneic stem cell transplant (alloSCT) outcomes of 86 adult ALL patients in complete remission (CR)...
3.
Singh V, Kim S, Deol A, Uberti J, Modi D
Leuk Lymphoma
. 2021 Dec;
63(4):855-864.
PMID: 34866528
T-cell lymphoma (TCL) poses a therapeutic challenge. Allogeneic stem cell transplant (alloSCT) is frequently offered in primary refractory disease or failed autologous transplant. We systematically searched published articles on outcomes...
4.
Albanyan O, Alkassis S, Kim S, Kin A, Alavi A, Ayash L, et al.
Hematol Oncol Stem Cell Ther
. 2021 Aug;
16(2):154-157.
PMID: 34425096
Mantle cell lymphoma is a rare subtype of non-Hodgkin's lymphoma with poor prognosis and continue to be challenging to treat. The choice of first line induction regimen remains a topic...
5.
Modi D, Kondrat K, Kim S, Deol A, Ayash L, Ratanatharathorn V, et al.
Transplant Cell Ther
. 2021 Jun;
27(9):760-767.
PMID: 34174469
Limited information is available on the efficacy of post-transplantation cyclophosphamide (PTcy) or thymoglobulin for graft-versus-host disease (GVHD) prophylaxis in mismatched unrelated donor (MMUD) transplants. We retrospectively compared outcomes of 76...
6.
Modi D, Chi J, Kim S, Deol A, Ayash L, Ratanatharathorn V, et al.
Transplant Cell Ther
. 2021 May;
27(8):665.e1-665.e7.
PMID: 33991722
Fludarabine 30 mg/m/d × 5 and melphalan 140 mg/m × 1 (Flu-Mel140) is a commonly used reduced-intensity conditioning regimen. We hypothesized that addition of 200cGy total body irradiation (TBI) to...
7.
Modi D, Albanyan O, Kim S, Deol A, Ayash L, Ratanatharathorn V, et al.
Leuk Lymphoma
. 2021 Feb;
62(8):1982-1989.
PMID: 33627028
The information on the impact of cytokine release syndrome (CRS) on haploidentical donor peripheral blood stem cell transplant (haploPBSCT) outcomes is limited. We retrospectively evaluated 98 patients who underwent haploPBSCT...
8.
Modi D, Singh V, Kim S, Ayash L, Deol A, Ratanatharathorn V, et al.
Ann Hematol
. 2021 Feb;
100(4):969-978.
PMID: 33594448
A head-to-head comparison of outcomes of unrelated donor allogeneic peripheral blood stem cell transplantation for AML between reduced intensity conditioning (RIC) and myeloablative conditioning (MAC) regimens using thymoglobulin for GVHD...
9.
Modi D, Kim S, Deol A, Ayash L, Ratanatharathorn V, Uberti J
Bone Marrow Transplant
. 2020 Oct;
56(3):741-744.
PMID: 33060839
Limited information is available on the impact of intensity of conditioning regimens in haploidentical peripheral blood stem cell transplant (haploPBSCT) with post-transplant cyclophosphamide (PTcy). We retrospectively compared outcomes of haplo-PBSCT...
10.
Singh V, Jang H, Kim S, Ayash L, Alavi A, Ratanatharathorn V, et al.
Leuk Lymphoma
. 2020 Oct;
62(2):446-453.
PMID: 33043743
The use of G-CSF post allogeneic transplant has become a common practice to accelerate neutrophil engraftment. There is some controversy in its use. To further evaluate the effectiveness, we compared...